About US

Y-Trap is a startup in South San Francisco developing novel fusion proteins for cancer immunotherapy, founded by Johns Hopkins and Stanford scientists. While current immunotherapies aim to activate and expand T cells by blocking immune checkpoints, they do not correct the immunosuppressive & tumor-promoting phenotypes of immune cells that dominate in the tumor. Y-Trap has utilized its versatile computational engineering platform to develop a portfolio of antibody-ligand traps (“Y-traps”) designed to counteract the determinants of these tumor-promoting immune cell phenotypes. Y-Trap is currently advancing its lead programs towards first-in-human clinical studies. 

Email us at info@y-trap.com to get in touch.